<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760717</url>
  </required_header>
  <id_info>
    <org_study_id>2000029811</org_study_id>
    <nct_id>NCT04760717</nct_id>
  </id_info>
  <brief_title>Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage (REDUCE)</brief_title>
  <acronym>REDUCE</acronym>
  <official_title>Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage (REDUCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether blood pressure treatment regimens&#xD;
      with spironolactone are better than blood pressure treatment regimens without spironolactone&#xD;
      at lowering blood pressure in brain hemorrhage survivors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pragmatic, randomized, open-label, blinded-endpoint trial comparing&#xD;
      spironolactone-containing antihypertensive regimens versus standard antihypertensive regimens&#xD;
      based on the 2017 AHA/ACC guidelines in intracerebral hemorrhage (ICH) survivors.&#xD;
&#xD;
      This study will randomize a total of 200 patients, 100 of each white and non-white patients,&#xD;
      between 3 weeks to 6 months after ICH to an antihypertensive regimen with spironolactone once&#xD;
      daily or standard BP control based on the 2017 AHA/ACC guidelines for 1 year.&#xD;
&#xD;
      Participants will undergo baseline testing for neurohormonal levels and will be followed for&#xD;
      12 months with regular assessment of home BP readings. The primary outcome of home systolic&#xD;
      BP will be measured at 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average change in home systolic blood pressure at 3 months</measure>
    <time_frame>Baseline, 3 month</time_frame>
    <description>The average home systolic blood pressure will be measured using a home blood pressure cuff</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving BP &lt; 130/80 mm Hg</measure>
    <time_frame>3 months</time_frame>
    <description>The proportion of patients achieving BP &lt; 130/80 mm Hg at 3 months will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antihypertensive medications at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>The number of antihypertensive medications at 3 months will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antihypertensive medications at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>The number of antihypertensive medications at 1 year will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke, myocardial infarction, or death</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of stroke of any type (ischemic or hemorrhagic), myocardial infarction, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Rankin Scale score</measure>
    <time_frame>Baseline, 1 year</time_frame>
    <description>Measure of neurologic disability (0=no disability to 6=dead)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Spironolactone</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized to the Standard care arm will be receiving their normal routine blood pressure treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone Pill</intervention_name>
    <description>Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. Symptomatic ICH confirmed by head CT or brain MRI during hospitalization&#xD;
&#xD;
          3. Written, informed consent by patient or surrogate&#xD;
&#xD;
          4. Ability to comply with all study procedures and available for the duration of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary ICH due to trauma, vascular malformation, or tumor&#xD;
&#xD;
          2. Life expectancy &lt; 1 year&#xD;
&#xD;
          3. eGFR &lt;45&#xD;
&#xD;
          4. Serum potassium greater than or equal to the upper limit of normal of the lab on the&#xD;
             two most recent consecutive potassium levels prior to enrollment&#xD;
&#xD;
          5. Known hypersensitivity to spironolactone&#xD;
&#xD;
          6. Upper arm greater than 17 inches in circumference&#xD;
&#xD;
          7. Pregnancy, planned pregnancy, or breastfeeding&#xD;
&#xD;
          8. Contraindication to discontinuing mineralocorticoid antagonist therapy for 3-12 months&#xD;
             per the investigator's discretion (e.g., refractory proteinuria)&#xD;
&#xD;
          9. Systolic BP &gt;200 mmHg or diastolic BP &gt;110 mmHg at the time of randomization&#xD;
&#xD;
         10. Systolic BP &lt;120 mmHg at the time of randomization&#xD;
&#xD;
         11. Any condition which, in the judgement of the investigator, increases the risk to the&#xD;
             patient&#xD;
&#xD;
         12. History of Addison's disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Sheth, MD</last_name>
      <phone>203-737-8051</phone>
      <email>kevin.sheth@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Sheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

